Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Just remember, 2:30 is critical here, that's around the time we see news and filings, hold the line. $RGBP
LOL, you must be new...LMFAO, "nobody, no one, never" funny....I'm sure a lot of people call you constantly for financial advice. lol
These shorts will get so burned, and I hope that people finally realized how reckless it was of them to sell any shares below 2 cents and how naive they were to think they can still get a bid filled below a penny. $RGBP
Sweet day for $RGBP shareholders...those that got shook didn't deserve this stock, enjoy your weekend. $RGBP
That's why he sold a small portion to a 3rd party for cash in hand.
Here's THE MONEY>
https://seekingalpha.com/filing/5471088
Item 1.01 Entry into a Material Definitive Agreement.
On April 7, 2021 Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) with Oncology Pharma, Inc. (“Licensee”) whereby Regen granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property ( “License IP”) for the treatment in humans of pancreatic cancer for a term of fifteen years from April 7, 2021.
The License IP consists of antigen specific cancer vaccines in which modified mRNA is administered to produce epitopes able to produce an immune response which augments likelihood of successful induction of immunity. An epitope is the part of an antigen that is recognized by the immune system.
As consideration to Regen for the rights and license granted pursuant to the Agreement Licensee shall:
(a) pay to Regen a nonrefundable fee of $55,000 no later than April 20,2021
(b) pay to Regen royalties equal to five percent (5%) of the Net Sales as Net Sales are defined in the Agreement of any Licensed Products in a quarter.
(c) pay to Regen ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Licensee from sublicensees, excluding royalties from sublicensees based on Net Sales of any Licensed Products for which Regen receives payment
Licensed Product is defined in the Agreement as (a) any method, procedure, service or process that incorporates, uses, used, is covered by, infringes or would infringe any of the License IP in the U.S. or foreign jurisdictions; and (b) any apparatus, material, equipment, machine or other product that incorporates, uses, used, is covered by, infringes or would infringe any of the License IP in the U.S. or foreign jurisdictions but for the rights granted pursuant to the Agreement.
In the event that development of the License IP by the Licensee is not commenced as of the date that is nine months from the effective date of the Agreement the rights and license granted pursuant to the Agreement shall become nonexclusive.
The foregoing description of the Agreement is not complete and is qualified in its entirety by reference to the text of the Agreement , which is attached to this Current Report on Form 8-K as Exhibit 10.1 and incorporated in this Item 1.01 by reference.
On April 7, 2021 KCL Therapeutics, Inc. (“KCL”) entered into an agreement (“Agreement”) with Oncology Pharma, Inc. (“Licensee”) whereby KCL granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property (“License IP”) for the treatment in humans of colon cancer for a term of fifteen years from April 7, 2021.
As consideration to KCL for the rights and license granted pursuant to the Agreement Licensee shall:
(a) pay to KCL a nonrefundable fee of Fifty Thousand common shares of Oncology Pharma, Inc. no later than April 20,2021
(b) pay to KCL royalties equal to five percent (5%) of the Net Sales as Net Sales are defined in the Agreement of any Licensed Products in a quarter.
(c) pay to KCL ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Licensee from sublicensees, excluding royalties from sublicensees based on Net Sales of any Licensed Products for which KCL receives payment
Licensed Product is defined in the Agreement as (a) any method, procedure, service or process that incorporates, uses, used, is covered by, infringes or would infringe any of the License IP in the U.S. or foreign jurisdictions; and (b) any apparatus, material, equipment, machine or other product that incorporates, uses, used, is covered by, infringes or would infringe any of the License IP in the U.S. or foreign jurisdictions but for the rights granted pursuant to the Agreement.
In the event that development of the License IP by the Licensee is not commenced as of the date that is nine months from the effective date of the Agreement the rights and license granted pursuant to the Agreement shall become nonexclusive.
KCL Therapeutics, Inc. is a wholly owned subsidiary of Regen Biopharma, Inc.
The foregoing description of the Agreement is not complete and is qualified in its entirety by reference to the text of the Agreement , which is attached to this Current Report on Form 8-K as Exhibit 10.2 and incorporated in this Item 1.01 by reference.
You asked 2 questions with one post to which you have no answer for...that implies you recognize your lack of wisdom and Due Diligence as well as your will to acknowledge that others on this board are more experienced than you are.
This company has money, the selling is not related to the company's assets, and those who sell are shortsighted, simple as that.
Like I said, I'm not worried, we might see the Yield sign up this week, and from all the buzz I really think we might wake up to $1 PPS trading on Nasdaq one day.
Besides,,,,$RGBP was trading on OTCQB I'm sure they are eligible since we've been trading above a penny longer than 30 days required to uplist.
That's huge, to say the least, I'm all in. $RGBP
That's more than a month away, we'll be current by then, Koos didn't come this far only to choke in the last lap, I'm not worried at all. $RGBP
You could basically say we closed unchanged, meanwhile over 138 mil shares traded today.
Nice close, $RGBP never fails to impress.
I told them not to dance to the MM's tune, ..Ohh well. $RGBP
These are notes issued last year in June 2020 with an exercise price of 0.025.
Read the 10Q.
https://www.sec.gov/Archives/edgar/data/1589150/000160706221000257/rgbp063020form10q.htm
Transaction Event” shall mean either of:
(a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party
(b) The granting of a license by the Company or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property
(v) That date which is twenty four (24) months subsequent to the date of execution of this Note.
The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest.
In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.025 per share.
The warrants shall be exercisable:
In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company (“Prepayment Date”)
In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note
As of June 30, 2020 $50,000 of the principal amount of the Note remains outstanding.
Don't dance with the MM's, play your hand, not theirs, let them dance themselves out. $RGBP
Bullish trend, a lot of buying pressure in effect, time to break free.
Enjoy your evening, see you at the Bell tomorrow morning, 16 % daily and we'll be there in no time, I expect a major squeeze this week pending great news, if you held this long, this is the time to hold longer if you want to really see the blue skies, next Candle will shoot us past 10 cents.
GLTA
$RGBP
Watch and learn. Just when you think the stock will crack, is when it flies higher. Besides...smart investors that did their research and DD will not settle for less than 20 cents here. $RGBP
And just like that, you lost your shares LMFAO. Don't hate the palyer, hate the game . $RGBP
The MM's are trying to trigger Stop-Loss orders, be careful don't loose your shares so early in the game. $RGBP
Heavy accumulation, volume has been steady over 100 Mil shares daily for the last 4 trading days with at least 15% growth daily. $RGBP
Patience is Bliss, just like that we will break a new HOD. Have some faith fellas, stop babysitting this stock already. $RGBP
Thursday peeps complained about a wall at 0.0155, we now trade at 0.0280. Now they complain about not breaking 3, meanwhile we'll be at 5 cents on Friday. LMFAO
But it will, patience, 2 full hours of trading, hang in there. Regen is known to put out PR's at about 2:30 PM,...you never know. $RGBP
By the end of the year they will throw in the towel, word of the day, "Don't be like Melvin". $RGBP
Funny how that pushes the PPS up constantly. LMFAO $RGBP
It's Ok, WSB will break them, they will crack soon. They lost complete control of their finances, they are down 50% on their entire portfolio. $RGBP
There's nothing funnier than a desperate MM scrambling for shares. $RGBP
Great Post by PennyPusher, everyone that doubts this company or thinks is just a flip stock should read it.
PennyPusher786 Post
Regen BioPharma Inc
About the company
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP) focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6. The company also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).
AREAS OF INTEREST
Hematopoiesis (Blood formation)
Breast Cancer
Liver Cancer
Leukemia
Myelodysplastic Syndrome
Aplastic Anemia
CLINICAL TRIALS
https://www.regenbiopharmainc.com/products.html
HemaXellerate
Aplastic Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS
dCellVax
Breast Cancer – dCellVax - IND #16200
CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.”
DiffronC
Myelodysplastic Syndrome Gene Silencing – DiffronC
DiffronC is a novel form of therapy called differentiation therapy that is expected to have much milder toxicity than chemotherapy. The mechanism of action is to correct the specific genes that prevent the myelodysplastic syndrome stem cell from producing mature blood cells.
Filings This Year:
Received On: Period Ending:
10-Q 08/05/2021 06/30/2020
10-Q08/05/2021 03/31/2020
10-Q08/05/2021 12/31/2019
10-K08/04/2021 09/30/2020
8-K07/14/2021 07/08/2021
8-K07/13/2021 07/13/2021
8-K07/02/2021 06/16/2021
8-K06/30/2021 06/28/2021
8-K06/28/2021 06/28/2021
The price ran up to .0819 on Monday, April 12th 2021 with a few factors in mind...
#1 Licensing deals; 2 in particular related to cancer research, from which they will receive a percentage of profits in the form of Royalties etc...
#2 50K Cash + 50 thousand shares of Oncology Pharma Inc which at the time were valued close to 2 million U.S dollars
#3 24 Patents owned by Regen
#4 FOMO Buying based upon Countless OTC Tickers running on news IE ENZ!C TSN!P DPL$ GGI! ALP!P etc etc... what can you say, when the express train leaves, it doesn't make pit stops...
Dpl$ ran above 5 Cents in February, retraced immediately, stayed below 2 cents for 3 months and then made a rapid leap past 5 cents and touched .2020.... They have no revenue and no signed contracts to date...
RGBP has
- 2 signed deals
- booked revenues with money in the bank and more to come
- a CEO with wealth in millions which is public knowledge
- and 24 patents!
RECENTLY PUBLISHED ARTICLES:
August 7th 2021 - Insider Financial
https://insiderfinancial.com/4-penny-stocks-to-keep-an-eye-on-tsoi-rgbp-vitx-asti/181899/
August 5th 2021 - Top News Guide
https://topnewsguide.com/2021/08/05/regen-biopharma-otcmktsrgbp-stock-is-in-news-what-to-expect-now/
July 30th 2021 - Microcap Daily
https://microcapdaily.com/regen-biopharma-inc-otcmkts-rgbp-biotech-sleeper-sitting-on-a-major-league-patent-portfolio/132392/
July 2nd 2021 - Microcap Daily
https://microcapdaily.com/regen-biopharma-inc-otcmkts-rgbp-major-runner-as-biotech-secures-valuable-nr2f6-cancer-t-cell-activation-patent/132063/
Getting Ready For A Monster-Run, Undoubtedly!
Better hands in $RGBP as of late, flippers have left the building.
I will look for you when this is at 20 cents....it's a promise.
$RGBP
Is it Monday yet ?
$RGBP
They managed to paint it down. lol, ...ahhh...the desperation...
That's why shorts know once you sell you cannot get in, so be smart and hold on to what you have, cause this ticker will be current next week but by then it will be past 5 cents to get in.
Besides..as you can see the stock is being bought daily, hell....is being bought now, maybe you need to change brokers.
$RGBP
I'm ok with 20% profits everyday from this stock for the next 15 years. The bank only pays under 2% yearly on your money. Keep'em coming. $RGBP
The CEO got money, he's sitting on a personal portfolio of $11 Mil, and sure as hell he knows his company is worth at least $1 PPS, he don't need to dilute he needs a big Market Cap of at least $2 Bil so he can become a Buyout candidate for Big Pharma or other big fish.
This company has no overhead to run the business and it's already guaranteed income for 15 years from ONPH just from one rented patent, this company has to be at at least $0.70 if not, anyone can buy out the whole float and take over the whole company overnight.
The Market Cap is a measly $80 Mil, a dude like Skhreli would buy this company today.
I've seen garbage paintings sell for more than that.
Anyone here thinks this is only worth 2 cents is very naïve.
Either way, we're golden, this is a long term investment for me.
$RGBP
Citadel clearing inventory to fight with Wallstreet Bets. This whole month of August you will see pops in the market unexpected. $RGBP
We need more dilution and more cow bell. LMFAO
All this dilution is pushing the stock higher. LMFAO